120, Huntington Ave

Boston,

MA,

USA,

ZIP: 02116

Phone:

Understand Mechanism of Action, Maximize Efficacy and Therapeutic Window, and Evaluate Long-Term Clinical Outcomes of Fc Receptor Pathway Targeting Biologics in Autoantibody Mediated Disease.

The field of FcRn receptor targeting is gaining ground-breaking speed as Argenx, Janssen, UCB and Immunovant compete to tackle myasthenia gravis and biopharma invest in transformative immunological therapy for autoimmune diseases as the next big drug opportunity.

The 3rd Fc Receptor Pathway Targeted Therapies Summit will once again feature unmissable conversations to advance targeting FcR and the subsequent generation of Fc manipulation since real-world proof and clinical value are now at the industry's fingertips.

Join 100+ of your colleagues at the 3rd Fc Receptor Pathway Targeted Therapies Summit - from the fields of immunology, antibody engineering, pharmacology, toxicology, and immuno-oncology for three days of content that is unmatched in its scope, all focused on the optimization of FcRn, FcyR, and novel Fc.

Put your stake in the ground to revolutionise autoimmune illness and position yourself in front of the next wave of blockbuster drug development.

URLs:
Tickets: https://go.evvnt.com/1525106-2?pid=1052
Brochure: https://go.evvnt.com/1525106-3?pid=1052

Prices:
Conference + 3 Workshops - Drug Developer: USD 4946.00,
Conference + 2 Workshops - Drug Developer: USD 4297.00,
Conference + 1 Workshop - Drug Developer: USD 3648.00,
Conference Only - Drug Developer : USD 2999.00,
Conference + 3 Workshops - Solution Provider: USD 6046.00,
Conference + 2 Workshops - Solution Provider: USD 5297.00,
Conference + 1 Workshop - Solution Provider : USD 4548.00,
Conference Only - Solution Provider : USD 2999.00,
Conference + 3 Workshops - Academic : USD 3696.00,
Conference + 2 Workshops - Academic : USD 3197.00

Speakers: Basil Golding Director FDA/CBER, Hans de Haard Chief Scientific Officer Argenx, David Humphreys Senior Director and Head of New Modality Therapeutics Protein Sciences UCB, Tony Shock Director UCB, Sally Ward Director of Translational Immunology University of Southampton, Anna Park Head of Protein Engineering and Biologics Research Sanofi, Armin Sepp Senior Principal Scientist Certara, Björn Frendéus Chief Scientific Officer  BioInvent, Harry Pappas senior consultant Adivo Associates LLC, Irina Rybina Principal Scientist and Group Leader - Downstream Process Assessment in Biotherapeutics and Integrated Biology Department, Gene and Pr Boehringer Ingelheim, Janet Peper-Gabriel Senior Scientist, Associate Director and Team Leader Pieris Pharmaceuticals, Jeanette Leusen Associate Professor - Center for Translational Immunology Research University Medical Center Utrecht, Joel Cohen-Solal Principal Scientist - Research  Abbvie, Julian Chandler Research Scientist Alexion Pharmaceuticals, Karen silence Head of Preclinical and Product Development argenx, Ken Howard Associate Professor  Aarhus University, Philip N.Moquist Senior Research Scientist Seagen, Po-Shun Lee Chief Medical Officer Generian, Rahul Raman Research Scientist Massachusetts Institute of Technology, Rodrigo Morales Senior scientist CSL Limited, Yuki Noguchi Scientist Chugai Pharmaceuticals